Which of the following conditions can be treated with pirenzepine?

Explanation

## Correct Answer: C. Peptic ulcer disease Pirenzepine is a selective **M₁ muscarinic antagonist** (antimuscarinic agent) that was historically used in peptic ulcer disease (PUD) management. Unlike non-selective anticholinergics, pirenzepine preferentially blocks M₁ receptors on gastric parietal cells, reducing gastric acid secretion without causing systemic anticholinergic side effects like dry mouth, urinary retention, or tachycardia. In the pre-proton pump inhibitor (PPI) era, pirenzepine was a standard DOC in India for PUD, particularly in patients intolerant to H₂ blockers. It reduces basal and stimulated gastric acid output by 30–50%, promoting ulcer healing. Although PPIs have now superseded pirenzepine in modern practice, it remains a valid answer in NEET PG because it demonstrates understanding of selective antimuscarinic pharmacology and the pathophysiology of acid-peptic disease. The M₁ selectivity is the discriminating feature—this is why pirenzepine works in PUD without causing the anticholinergic toxicity seen with atropine or hyoscine. ## Why the other options are wrong **A. Asthma** — Anticholinergics are **contraindicated** in asthma because they cause bronchial mucus plugging and airway obstruction. While ipratropium (an inhaled anticholinergic) is used in COPD, pirenzepine is never used in asthma. NBE traps students who confuse anticholinergic use across respiratory conditions. **B. Hypertension** — Pirenzepine has **no antihypertensive effect**. While some anticholinergics can cause reflex tachycardia and worsen hypertension, pirenzepine is not indicated for BP control. This is a distractor for students unfamiliar with pirenzepine's specific GIT action. **D. Glaucoma** — Anticholinergics are **contraindicated** in glaucoma because they cause pupillary dilation and increased intraocular pressure, worsening angle-closure glaucoma. Pilocarpine (a cholinergic agonist) is used in glaucoma, not anticholinergics. NBE exploits confusion between cholinergic and anticholinergic agents in ophthalmology. ## High-Yield Facts - **Pirenzepine** is a selective **M₁ muscarinic antagonist** used historically in peptic ulcer disease to reduce gastric acid secretion. - M₁ selectivity of pirenzepine means **minimal systemic anticholinergic side effects** (no dry mouth, urinary retention, or tachycardia) compared to non-selective agents like atropine. - Anticholinergics are **contraindicated in asthma and glaucoma** due to risk of bronchial plugging and raised intraocular pressure respectively. - In modern Indian practice, **PPIs (omeprazole, pantoprazole) and H₂ blockers (ranitidine, famotidine)** have replaced pirenzepine as first-line agents for PUD. - Pirenzepine reduces gastric acid output by **30–50%** and promotes ulcer healing in 4–8 weeks when used as monotherapy. ## Mnemonics **M₁ = Mucosa (Acid)** M₁ receptors on gastric parietal cells → pirenzepine blocks them → ↓ acid. Remember: M₁ = GIT, not M₂/M₃ (which are systemic). **ACME: Anticholinergics Contraindicated in Asthma & Myopia (Glaucoma)** Anticholinergics worsen asthma (mucus plugging) and glaucoma (mydriasis → ↑ IOP). Use this to eliminate options A and D immediately. ## NBE Trap NBE pairs pirenzepine with asthma and glaucoma to exploit the common misconception that "anticholinergics are safe in all conditions." Students who don't know pirenzepine's specific M₁ selectivity may incorrectly think anticholinergics are universally contraindicated, missing the correct answer. ## Clinical Pearl In Indian clinical practice, while pirenzepine is now rarely prescribed due to PPI dominance, it remains a classic NEET PG question because it tests understanding of selective receptor antagonism and acid-peptic disease pathophysiology—concepts that extend to modern H₂ blocker and PPI mechanisms. _Reference: KD Tripathi Pharmacology Ch. 48 (GIT Agents); Harrison Ch. 297 (Peptic Ulcer Disease)_